The nation of Zimbabwe has declined a substantial American health deal valued at $367m (£272m) over five years because of the United States' demand for confidential information.
The decision came to light after a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesman later explained that the US was requesting biological samples for scientific study and commercial purposes but was not willing to share the benefits from future medical innovations.
"We will now turn to the difficult and regrettable task of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for continued dialogue to secure a deal acceptable to both sides so the nation's critical HIV treatment initiative can be sustained.
Wider Context
This rejection follows a comparable situation in neighbouring Kenya, where a court halted a similar health funding agreement following legal challenges were filed about the security of citizens' medical information.
Since returning to office recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump argued its spending was "inefficient" and his administration was pursuing direct bilateral agreements to boost openness and accountability.
Based on statements, Sixteen African countries have to date signed similar health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership might have yielded significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving HIV treatment through American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, with no corresponding promise of access to any medical innovations – like new medicines or tests – that could result from that provided information," Mangwana explained.
"Put simply, our country would supply the raw materials for medical research without any assurance that the final treatments would be available to our population should a new health crisis emerge."
Sovereignty and Global Health
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining systems previously established via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to deal with potential pandemics.
"This framework is intended to ensure that when a nation contributes its information, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the funds to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome continued dialogue with our US partners on how subsequent co-operation could be arranged in a way that respects the sovereignty and interests of each country."
Medical Community Response
A leading public health body stated it recognised the official position, but recommended that talks need to persist given that a large portion of the nation's HIV programmes depended on foreign aid.
"If technical issues exist, such as those involving information security or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," it said.
This impasse emphasises the ongoing tensions between accepting much-needed international aid and protecting national sovereignty in an increasingly data-driven world.